19 Aug 2015 15:09
Mon, 11th Jan 2010 08:44
Stem cell therapy company Reneuron Group has raised £68.4m to focus on its core product and nanomedicine cancer programme through to the first half of 2019, while final results highlighted progress of its other projects. A placing of £68.4m at a price of 5p per share saw star UK fund manager Neil Wo
Read more